Art. -Nr.: HY-12724

Guanabenz

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Guanabenz is an orally active α-2-adrenoceptor agonist. Guanabenz has antihypertensive effect and antiparasitic activity. Guanabenz interferes ER stress-signalling and has protective effects in cardiac myocytes. Guanabenz also is used for the research of high blood pressure.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.85%
CAS. Nr.: 5051-62-7
Formel: C₈H₈Cl₂N₄
Molecular Weight:231.08

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Guanabenz Chemical Structure

CAS. Nr.: 5051-62-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Toxoplasma

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen :

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	4.85 μM Compound: Guanabenz	Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay	[PMID: 28230985]
HEK-293T	EC₅₀	0.09 μM Compound: 16a	Agonist activity at human TAAR1 receptor expressed in HEK293T cells cotransfected with beta-2 receptor assessed as cAMP production by BRET assay Agonist activity at human TAAR1 receptor expressed in HEK293T cells cotransfected with beta-2 receptor assessed as cAMP production by BRET assay	10.1039/C5MD00400D

In Vitro

Guanabenz (0.5-50 μM, 24 h) is treated with increasing concentrations for 24 hours not affect cell viability^[1].
Guanabenz (0.5-50 μM, 24 h) alone not affects the UPR targets, neither on mRNA or protein level nor the phosphorylation status of eIF2a. Guanabenz also not induces GADD34 or the constitutively active form CReP^[1].
Guanabenz (0.5-50 μM, 24 h) alone not induces ER stress in neonatal rat cardiomyocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Neonatal rat cardiac myocytes (NRCM)
Concentration:

0.5–50 μM
Incubation Time:

24 h
Result:

Did not affect cell survival.

RT-PCR^[1]

Cell Line:

Neonatal rat cardiac myocytes (NRCM)
Concentration:

0.5–50 μM
Incubation Time:

24 h
Result:

Did not affect levels of UPR targets.

Western Blot Analysis^[1]

Cell Line:

Neonatal rat cardiac myocytes (NRCM)
Concentration:

0.5–50 μM
Incubation Time:

24 h
Result:

Increased the levels of low panel concentration-dependent UPR targets proteins.

In Vivo

Guanabenz (5 mg/kg/day; i.p.; for 3 weeks) can reproducibly reduce brain cyst burden^[2].
Guanabenz (5 mg /kg/d, i.p., oral; 10 mg/kg/d, gavage; for 3 weeks) reverses Toxoplasma-induced hyperactivity in latently infected mice^[2].
Guanabenz (100 and 320 μg/kg and 1 mg/kg, i.v., over a period of 5 min at intervals of 40 min) reduces sympathetic outflow, heart rate and blood pressure in debuffered cats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/cJ mice^[2]
Dosage:

5 mg/kg
Administration:

5 mg/kg/day; i.p. ; for 3 weeks
Result:

Reduced the latent brain cysts in both male and female BALB/cJ mice.

Animal Model:

BALB/cJ mice^[2]
Dosage:

5 mg/kg; 10 mg/kg
Administration:

5 mg /kg/d, i.p., oral; 10 mg/kg/d, gavage; for 3 weeks
Result:

Reversed parasite-induced hyperactivity to near-baseline levels.

Animal Model:

Cats^[3]
Dosage:

100 and 320 μg/kg and 1 mg/kg
Administration:

100 and 320 μg/kg and 1 mg/kg, i.v., over a period of 5 min at intervals of 40 min
Result:

Declined markedly blood pressure and nerve activity.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 5051-62-7
Appearance Solid
Molecular Weight 231.08
Formel C₈H₈Cl₂N₄
Color White to off-white
SMILES

ClC1=C(/C=N/NC(N)=N)C(Cl)=CC=C1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All

Sort by:

Journal Impact Factor

Nature

CRISPR screens decode cancer cell pathways that trigger γδ T cell detection. [Abstract]

2023 Sep;621(7977):188-195. PMID: 37648854
Cancer Lett

Repurposing the Neurokinin-1 receptor antagonist Aprepitant to eradicate relapsed/refractory acute lymphoblastic leukemia via mitochondria-driven necroptosis. [Abstract]

2026 May 24:218621. PMID: 42184918
Cell Rep

Structural Basis of the Diversity of Adrenergic Receptors. [Abstract]

2019 Dec 3;29(10):2929-2935.e4. PMID: 31801060
Brain Res Bull

The neuroprotective effect of guanabenz combined with α-lipoic acid in the hSOD1-G93A amyotrophic lateral sclerosis model. [Abstract]

2026 Jun 1:239:111890. PMID: 41991114

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 16.67 mg/mL (72.14 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.3275 mL

21.6375 mL

43.2751 mL

5 mM

0.8655 mL

4.3275 mL

8.6550 mL

10 mM

0.4328 mL

2.1638 mL

4.3275 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Christiane Neuber, et al. Guanabenz interferes with ER stress and exerts protective effects in cardiac myocytes. PLoS One. 2014 Jun 3;9(6):e98893. [Content Brief]

[2]. Jennifer Martynowicz, et al. Guanabenz Reverses a Key Behavioral Change Caused by Latent Toxoplasmosis in Mice by Reducing Neuroinflammation. mBio. 2019 Apr 30;10(2):e00381-19. [Content Brief]

[3]. T Baum, et al. Studies on the centrally mediated hypotensive activity of guanabenz. Eur J Pharmacol. 1976 May;37(1):31-44. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.3275 mL	21.6375 mL	43.2751 mL	108.1876 mL
	5 mM	0.8655 mL	4.3275 mL	8.6550 mL	21.6375 mL
	10 mM	0.4328 mL	2.1638 mL	4.3275 mL	10.8188 mL
	15 mM	0.2885 mL	1.4425 mL	2.8850 mL	7.2125 mL
	20 mM	0.2164 mL	1.0819 mL	2.1638 mL	5.4094 mL
	25 mM	0.1731 mL	0.8655 mL	1.7310 mL	4.3275 mL
	30 mM	0.1443 mL	0.7213 mL	1.4425 mL	3.6063 mL
	40 mM	0.1082 mL	0.5409 mL	1.0819 mL	2.7047 mL
	50 mM	0.0866 mL	0.4328 mL	0.8655 mL	2.1638 mL
	60 mM	0.0721 mL	0.3606 mL	0.7213 mL	1.8031 mL

Keywords

Guanabenz

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Guanabenz

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Endoplasmic Reticulum Stress Compound Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Antiparasitic Compound library

Anti-Obesity Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cysteine Targeted Covalent Library

Cysteine Targeted Covalent Fragment Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Chinese Baijiu Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Guanabenz

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Guanabenz Related Classifications

HY-12724 Related Classifications